Genmab U.S., INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$4.3Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
8,149clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2021 $27K
2022 $252K
2023 $1.1M
2024 $1.7M
2025 $1.2M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Gynecologic Oncology $1.2M
Hematology & Oncology $1.2M
Medical Oncology $771K
Hematology (Internal Medicine) $238K
Family $196K
Obstetrics & Gynecology $152K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Bradley Monk West Palm Beach, FL Gynecologic Oncology $154,722.64
Heidi Godoy Albany, NY Gynecologic Oncology $109,551.62
Thomas Krivak Pittsburgh, PA Gynecologic Oncology $104,413.17
Scott Jordan Fort Lauderdale, FL Obstetrics & Gynecology $98,753.36
Chirag Shah Seattle, WA Gynecologic Oncology $96,387.01
Tara Graff Clive, IA Medical Oncology $84,789.04
Tiffany Redfern Fort Worth, TX Gynecologic Oncology $81,602.16
Joshua Kesterson Newport, PA Gynecologic Oncology $72,849.03
John Chan San Francisco, CA Gynecologic Oncology $66,737.93
Courtney Arn Franklin, OH Women'S Health (Nurse Practitioner) $64,613.85

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.